LifeStance Health Group (NASDAQ:LFST) Sees Unusually-High Trading Volume on Analyst Upgrade

LifeStance Health Group, Inc. (NASDAQ:LFST) saw an uptick in trading volume on Thursday after KeyCorp raised their price target on the stock from $8.00 to $9.00. KeyCorp currently has an overweight rating on the stock. 2,944,276 shares were traded during trading, an increase of 64% from the previous session’s volume of 1,795,452 shares.The stock last traded at $7.0950 and had previously closed at $7.41.

A number of other brokerages have also recently weighed in on LFST. Barclays began coverage on shares of LifeStance Health Group in a research note on Tuesday, December 9th. They set an “overweight” rating and a $8.00 price target for the company. Wall Street Zen raised shares of LifeStance Health Group from a “hold” rating to a “buy” rating in a report on Sunday, February 8th. BTIG Research raised their price target on LifeStance Health Group from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, February 2nd. UBS Group upped their price objective on LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LifeStance Health Group in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, LifeStance Health Group has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

Insider Activity

In other news, insider Ann Varanakis sold 50,000 shares of the stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $6.90, for a total transaction of $345,000.00. Following the completion of the transaction, the insider directly owned 315,610 shares of the company’s stock, valued at approximately $2,177,709. This represents a 13.68% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Robert Bessler sold 119,942 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $7.04, for a total value of $844,391.68. Following the completion of the sale, the director directly owned 1,318,983 shares of the company’s stock, valued at $9,285,640.32. This represents a 8.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 270,086 shares of company stock valued at $1,891,264 over the last three months. 3.20% of the stock is currently owned by corporate insiders.

More LifeStance Health Group News

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Q4 revenue and profitability improved materially — revenue rose 17% to $382.2M, full‑year revenue grew 14%, Q4 net income was $11.7M and adjusted EBITDA jumped 49%, signalling stronger demand and operating leverage. LifeStance Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Board approved a $100M share repurchase program (up to ~3.6% of outstanding shares), which supports buyback-driven capital return and signals management confidence. LifeStance Reports Fourth Quarter and Full Year 2025 Results
• Neutral Sentiment: Company provided 2026 guidance: revenue $1.615B–$1.655B and adjusted EBITDA $185M–$205M. Guidance is growth‑oriented but investors will monitor execution vs. the midpoint. LifeStance Reports Fourth Quarter and Full Year 2025 Results
• Neutral Sentiment: Some outlets emphasize that revenue and other metrics beat estimates (revenue beat consensus), while EPS coverage is mixed depending on the comparator — this creates divergent analyst/tone impact. LifeStance Health Group (NASDAQ:LFST) Posts Better-Than-Expected Sales In Q4 CY2025, Stock Jumps 12.7%
• Negative Sentiment: Reported EPS of $0.03 missed the consensus ~$0.05 (market‑reported miss), which likely disappointed short‑term earnings expectations despite revenue strength. LifeStance Health Group, Inc. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Selling stockholders launched a secondary offering of 25M shares (company not selling/receiving proceeds), creating immediate supply overhang and downward pressure on the float. LifeStance Health Group Announces Launch of Secondary Public Offering
• Negative Sentiment: Recent insider selling and some large institutional reductions noted in public data, which can amplify selling pressure and investor caution. QuiverQuant summary of Q4 results and insider activity

Hedge Funds Weigh In On LifeStance Health Group

A number of institutional investors and hedge funds have recently made changes to their positions in LFST. Larson Financial Group LLC increased its holdings in shares of LifeStance Health Group by 19,952.6% in the 4th quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock valued at $27,000 after purchasing an additional 3,791 shares in the last quarter. Bayesian Capital Management LP acquired a new position in LifeStance Health Group during the second quarter worth about $52,000. Krane Funds Advisors LLC purchased a new position in LifeStance Health Group in the fourth quarter valued at about $71,000. Vanguard Personalized Indexing Management LLC purchased a new position in LifeStance Health Group in the third quarter valued at about $72,000. Finally, Cibc World Markets Corp acquired a new stake in shares of LifeStance Health Group during the 4th quarter valued at approximately $77,000. 85.50% of the stock is owned by institutional investors and hedge funds.

LifeStance Health Group Price Performance

The firm has a market cap of $2.74 billion, a PE ratio of -234.83 and a beta of 1.12. The company has a current ratio of 1.58, a quick ratio of 1.58 and a debt-to-equity ratio of 0.18. The company has a 50 day moving average price of $7.12 and a 200 day moving average price of $6.18.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings data on Wednesday, February 25th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.02). The firm had revenue of $382.20 million during the quarter, compared to analysts’ expectations of $378.51 million. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The business’s revenue for the quarter was up 17.4% on a year-over-year basis. During the same period in the previous year, the business earned ($0.01) earnings per share. On average, sell-side analysts expect that LifeStance Health Group, Inc. will post -0.18 EPS for the current year.

LifeStance Health Group declared that its Board of Directors has authorized a share repurchase plan on Wednesday, February 25th that permits the company to repurchase $100.00 million in shares. This repurchase authorization permits the company to reacquire up to 3.6% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.